Home Blood Brain Barrier (BBB) NIH R61/R33 Trans-Agency Blood-Brain Interface Program (Clinical Trials Not Allowed)

NIH R61/R33 Trans-Agency Blood-Brain Interface Program (Clinical Trials Not Allowed)

107
0
NIH R61/R33 Trans-Agency Blood-Brain Interface Program (Clinical Trials Not Allowed)

The Department of Defense Joint Program Committee-6 (JPC-6) Combat Casualty Care Research Program (CCCRP) has collaborated with the National Heart, Lung, and Blood Institute (NHLBI) to promote a new initiative by publishing a Funding Opportunity Announcement (FOA). This FOA establishes a trans-agency program to support collaborations between hematologists/vascular experts, neuroscientists, and blood-brain barrier (BBB) tissue chip developers for high risk/high reward research to create enhanced/modified platforms that more closely model the human BBB. 

The first application due date is December 2, 2019. See the link below to submit an application.

Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models.

Call to Action: This is a U.S. Department of Defense Joint Program Committee procurement opportunity.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.